Another important milestone achieved by the Glycanostics team!
Via the Crowdberry Investment Platform, we presented our highly accurate diagnostic test to private investors in September 2021 and raised an additional investment of €690,000. With the help of our investors we can now be strong players in innovation processes and drive healthcare transformation in diagnostics in the coming years. Our highly accurate diagnostic test with its unique mode of action reflects our innovative approach to diagnostics and we look forward to networking and connecting with the wider pharma community to be closer to patients and render our mission ever more successful.
The capital thus provided in a total of €1 milion was financed in a co-investment together with the CB Growth ONE investment fund. Glycanostics is the third company from Crowberry’s portfolio (after MultiplexDX and Sensoneo) and the third in the history of Slovakia to have received an EIC grant.
The Crowdberry investment platform enables private investors to invest directly in Czech and Slovak companies and real estate. It has been changing the way companies are financed since 2015. Companies can raise capital for growth and business development in a transparent way with the possibility of integrating their customers into the ownership structure and gaining access to the ecosystem of innovative companies known as smart investors and partners. So far, Crowdberry investors have provided capital worth more than €30 million to companies such as Footshop, GymBeam, MultiplexDX, Boataround, Ecocapsule, and others. At the beginning of 2021, the company introduced a real estate fund of qualified investors in Prague, CB Property Investors, that focused on investments in real estate with the potential for increasing value. In Slovakia, Crowdberry manages an investment fund in the amount of €23 million through a subsidiary called CB Investment Management to support start-ups.
